Pralsetinib is a first-generation targeted drug

Pralsetinib (Pralsetinib) is a third-generation targeted drug, also known as a RET inhibitor. It is mainly used to treat non-small cell lung cancer, thyroid cancer and other RET fusion-positive solid tumors carrying RET gene mutations. Third-generation targeted drugs generally have higher selectivity and stronger inhibitory activity and can target more types of mutations to provide better therapeutic effects.

Platinib is a kinase inhibitor of wild-typeRET and oncogenic RET fusions and mutations. Certain RET fusion proteins and activating point mutations can drive tumorigenic potential through overactivation of downstream signaling pathways, leading to uncontrolled cell proliferation. Praxitinib shows antitumor activity in cultured cells and in animal tumor transplant models harboring oncogenic RET fusions or mutations. Platinib is provided in the form of oral capsules. The recommended dose is 400 mg once daily on an empty stomach. No food should be eaten for at least 2 hours before and for at least 1 hour after taking Platinib.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.